KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Net Margin (2016 - 2025)

Rigel Pharmaceuticals has reported Net Margin over the past 15 years, most recently at 384.04% for Q4 2025.

  • Quarterly results put Net Margin at 384.04% for Q4 2025, up 35914.0% from a year ago — trailing twelve months through Dec 2025 was 124.72% (up 11497.0% YoY), and the annual figure for FY2025 was 124.72%, up 11497.0%.
  • Net Margin for Q4 2025 was 384.04% at Rigel Pharmaceuticals, up from 40.17% in the prior quarter.
  • Over the last five years, Net Margin for RIGL hit a ceiling of 384.04% in Q4 2025 and a floor of 164.0% in Q1 2022.
  • Median Net Margin over the past 5 years was 11.51% (2023), compared with a mean of 3.87%.
  • Biggest five-year swings in Net Margin: crashed -21275bps in 2022 and later skyrocketed 35914bps in 2025.
  • Rigel Pharmaceuticals' Net Margin stood at 110.91% in 2021, then skyrocketed by 102bps to 2.73% in 2022, then fell by -25bps to 2.06% in 2023, then soared by 1109bps to 24.9% in 2024, then skyrocketed by 1442bps to 384.04% in 2025.
  • The last three reported values for Net Margin were 384.04% (Q4 2025), 40.17% (Q3 2025), and 58.63% (Q2 2025) per Business Quant data.